{"id":33457,"date":"2020-08-13T11:23:06","date_gmt":"2020-08-13T10:23:06","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33457"},"modified":"2023-05-02T22:14:09","modified_gmt":"2023-05-02T21:14:09","slug":"emile-van-corven","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/","title":{"rendered":"Emile van Corven"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Dr. Emile van Corven<\/h2>\n<h4>Chief Development Officer at Bioceros<\/h4>\n\t<p>Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry: global head of process development and pilot plant GMP manufacturing of MAbs and vaccines (Crucell\/J&amp;J), and the development or recombinant proteins (Pharming). He was also head of the regulatory authority control lab for the release of blood products\/vaccines, and head of the regulatory group for review of biotech CMC dossiers. He was a post-doc at The Netherlands Cancer Institute in Amsterdam, and got his PhD in 1987 at Nijmegen University. He published over 30 peer-reviewed scientific articles, chapters in textbooks, and various patents. From 2012 till date he is member of the editorial board of &#8220;Pharmaceutical Bioprocessing&#8221;.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2.jpg\" alt=\"Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-201x300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-686x1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-768x1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-630x940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-420x627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros_2-315x470.jpg 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Solve the technical challenges in developing biosimilar antibodies\n\t<\/h3>\n<ul>\n<li>High titer processes<\/li>\n<li>Modulation of quality attributes<\/li>\n<li>Decrease in COGs<\/li>\n<li>High throughput analytical methods<\/li>\n<\/ul>\n\t<a href=\"https:\/\/sociopharma.com\/\" target=\"_blank\" role=\"button\" rel=\"noopener\">\n\t\t\t\t\tPresentation available only at SocioPharma.com\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/polpharma.pl\/en\/\" target=\"_blank\" rel=\"noopener\">https:\/\/polpharma.pl\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/emile-van-corven-1bb6122\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Dr. Emile van Corven Chief Development Officer at Bioceros Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry: global head of process development and pilot plant GMP manufacturing of MAbs and vaccines (Crucell\/J&amp;J), and the development or recombinant proteins (Pharming)&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":33458,"parent":33455,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33457","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emile van Corven &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry:\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emile van Corven &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry:\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-02T21:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/\",\"name\":\"Emile van Corven &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros.jpg\",\"datePublished\":\"2020-08-13T10:23:06+00:00\",\"dateModified\":\"2023-05-02T21:14:09+00:00\",\"description\":\"Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry:\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars &#038; Biologics 2019 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Emile van Corven\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emile van Corven &#8226; BioTech Pharma Summit","description":"Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry:","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/","og_locale":"en_US","og_type":"article","og_title":"Emile van Corven &#8226; BioTech Pharma Summit","og_description":"Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry:","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2023-05-02T21:14:09+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/","name":"Emile van Corven &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros.jpg","datePublished":"2020-08-13T10:23:06+00:00","dateModified":"2023-05-02T21:14:09+00:00","description":"Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry:","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Emile_Van_Corven_BioTech_Pharma_Summit_Bioceros.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/emile-van-corven\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Biosimilars &#038; Biologics 2019 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/biosimilars-biologics-2019-speakers\/"},{"@type":"ListItem","position":3,"name":"Emile van Corven"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33457"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33457\/revisions"}],"predecessor-version":[{"id":38293,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33457\/revisions\/38293"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33455"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/33458"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}